


Financial Results of Fiscal Year Ended June 2025

August 14, 2025



**(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)**

Note: This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.

Contents

- 1. Summary of Consolidated Financial Results of FYE June 2025**
- 2. Earnings Forecast for FYE June 2026**

FYE June 2025 Main Points - 1

Revenue 120,025 Mil.Yen <Year-on-year +11.6%>

**Progressed favorably primarily on Medical Division (domestic / overseas)
due to expanding demand**

- **Medical Division ~Strong performance in both Cardiovascular and Non-cardiovascular~**
 - **Cardiovascular field:** Increased mainly in PCI GW and Penetration Catheter in all regions
 - **Non-Cardiovascular field:** Increased in all regions across all areas including Peripheral, Neurovascular, Abdominal and Gastrointestinal
 - **OEM business:** Decreased mainly in the U.S. and China
- **Device Division ~ Slight increase in Medical Components and slight decrease in Industrial Components ~**
 - **Medical Components business:** Increased transactions of cardiovascular inspection catheter components for Asia
 - **Industrial Components business:** Decreased in overseas leisure-related transactions
- **Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +309 Mil. Yen**

| Exchange rate (Unit : JPY) | US \$ | EURO | CNY | BAHT |
|-------------------------------|--------|--------|-------|------|
| FYE June 2025 | 149.72 | 162.83 | 20.73 | 4.41 |
| FYE June 2024 | 149.39 | 161.48 | 20.64 | 4.17 |

FYE June 2025 Main Points - 2

Operating income 30,079 Mil. Yen <YoY +35.9%>

Net income 12,737 Mil. Yen <YoY -19.4%>

Operating income increased significantly due to a significant improvement in the gross profit margin.

But Net income for the current period decreased due to the recording of impairment losses.

■ Gross profit: 81,235 Mil.Yen < YoY +17.6% >

- Increased due to higher sales and an increase in gross profit margin (64.2% → 67.7%) accompanying productivity improvement.

■ Operating income: 30,079 Mil.Yen <YoY +35.9% >

- Increased in sales-related expenses both domestically and internationally due to increased revenue and strengthened promotional activities in the U.S. and Japan
- Increased in R&D expenses (12,248 Mil.Yen) (YoY +585 Mil.Yen, R&D-to-Revenue ratio 10.2 %)

■ Ordinary income: 29,563 Mil.Yen <YoY +34.6% >

- Non-operating income: Increased in subsidy income (YoY +838 Mil.Yen)
- Non-operating expenses: Increased in foreign exchange losses (YoY +1,075 Mil.Yen)

■ Net income attributable to parent company shareholders: 12,737 Mil.Yen <YoY -19.4% >

- Extraordinary losses: Booking impairment losses (YoY +9,244 Mil.Yen)
Booking loss on valuation of investment securities (YoY +968 Mil.Yen)
Booking loss on valuation of shares of subsidiaries and associates, and booking provision of allowance for doubtful accounts for subsidiaries and associates (YoY +687 Mil.Yen)

Highlights Year-on-Year

| | FYE June 2024 Results | | FYE June 2025 Results | | | (Reference) | | | | | | | | | | | | | | | | | | | | | | | |
|---|--------------------------|--------------|--------------------------|--------------|-----------------------|----------------|----------------------|--------------|---------|-------|------|-----|------|--------|--------|-------|------|--------|--------|-------|------|------|------|-----|------|--------|--------|-------|------|
| | Amount (Mil.Yen) | Ratio (%) | Amount (Mil.Yen) | Ratio (%) | YoY | | Amount (Mil.Yen) | Ratio (%) | YoY | | | | | | | | | | | | | | | | | | | | |
| | | | | | Changes (Mil.Yen) | Changes (%) | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue | 107,547 | 100.0 | 120,025 | 100.0 | +12,477 | +11.6 | 119,715 | 100.0 | +12,168 | +11.3 | | | | | | | | | | | | | | | | | | | |
| Gross Profit | 69,053 | 64.2 | 81,235 | 67.7 | +12,182 | +17.6 | 81,849 | 68.4 | +12,796 | +18.5 | | | | | | | | | | | | | | | | | | | |
| Operating Income excluding goodwill amortization, etc. | 24,168 | 22.5 | 31,689 | 26.4 | +7,521 | +31.1 | 32,495 | 27.1 | +8,327 | +34.5 | | | | | | | | | | | | | | | | | | | |
| Operating Income | 22,135 | 20.6 | 30,079 | 25.1 | +7,943 | +35.9 | 30,891 | 25.8 | +8,755 | +39.6 | | | | | | | | | | | | | | | | | | | |
| Ordinary Income | 21,968 | 20.4 | 29,563 | 24.6 | +7,595 | +34.6 | | | | | | | | | | | | | | | | | | | | | | | |
| Net income attributable to parent company shareholders | 15,808 | 14.7 | 12,737 | 10.6 | -3,070 | -19.4 | | | | | | | | | | | | | | | | | | | | | | | |
| EPS (yen) | 58.20 | – | 46.92 | – | -11.28 | -19.4 | | | | | | | | | | | | | | | | | | | | | | | |
| Exchange rate (Unit : JPY) <table border="1" style="margin-left: 20px;"> <tr> <td>US\$</td> <td>EURO</td> <td>CNY</td> <td>BAHT</td> </tr> <tr> <td>149.72</td> <td>162.83</td> <td>20.73</td> <td>4.41</td> </tr> <tr> <td>149.39</td> <td>161.48</td> <td>20.64</td> <td>4.17</td> </tr> </table> | | | | | | | | | | US\$ | EURO | CNY | BAHT | 149.72 | 162.83 | 20.73 | 4.41 | 149.39 | 161.48 | 20.64 | 4.17 | | | | | | | | |
| US\$ | EURO | CNY | BAHT | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 149.72 | 162.83 | 20.73 | 4.41 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 149.39 | 161.48 | 20.64 | 4.17 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| FYE June 2025 <table border="1" style="margin-left: 20px;"> <tr> <td>US\$</td> <td>EURO</td> <td>CNY</td> <td>BAHT</td> </tr> <tr> <td>149.72</td> <td>162.83</td> <td>20.73</td> <td>4.41</td> </tr> <tr> <td>149.39</td> <td>161.48</td> <td>20.64</td> <td>4.17</td> </tr> </table> FYE June 2024 <table border="1" style="margin-left: 20px;"> <tr> <td>US\$</td> <td>EURO</td> <td>CNY</td> <td>BAHT</td> </tr> <tr> <td>149.39</td> <td>161.48</td> <td>20.64</td> <td>4.17</td> </tr> </table> | | | | | | | | | | US\$ | EURO | CNY | BAHT | 149.72 | 162.83 | 20.73 | 4.41 | 149.39 | 161.48 | 20.64 | 4.17 | US\$ | EURO | CNY | BAHT | 149.39 | 161.48 | 20.64 | 4.17 |
| US\$ | EURO | CNY | BAHT | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 149.72 | 162.83 | 20.73 | 4.41 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 149.39 | 161.48 | 20.64 | 4.17 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US\$ | EURO | CNY | BAHT | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 149.39 | 161.48 | 20.64 | 4.17 | | | | | | | | | | | | | | | | | | | | | | | | | | |

Highlights Compared to the Plan

| | FYE June 2025 Revised Plan | | FYE June 2025 Results | | | Compared to the Revised Plan | |
|---|----------------------------|--------------|-----------------------|--------------|------------------------------|------------------------------|--|
| | Amount (Mil.Yen) | Ratio (%) | Amount (Mil.Yen) | Ratio (%) | Compared to the Revised Plan | | |
| | | | | | Changes (Mil.Yen) | Changes (%) | |
| Revenue | 119,160 | 100.0 | 120,025 | 100.0 | +864 | +0.7 | |
| Gross Profit | 80,056 | 67.2 | 81,235 | 67.7 | +1,178 | +1.5 | |
| Operating Income excluding goodwill amortization, etc. | 30,476 | 25.6 | 31,689 | 26.4 | +1,213 | +4.0 | |
| Operating Income | 28,859 | 24.2 | 30,079 | 25.1 | +1,220 | +4.2 | |
| Ordinary Income | 28,987 | 24.3 | 29,563 | 24.6 | +575 | +2.0 | |
| Net income attributable to parent company shareholders | 11,314 | 9.5 | 12,737 | 10.6 | +1,422 | +12.6 | |
| EPS (yen) | 41.66 | — | 46.92 | — | +5.26 | +12.6 | |

| Exchange rate (Unit : JPY) | US \$ | EURO | CNY | BAHT |
|----------------------------|--------|--------|-------|------|
| FYE June 2025 Results | 149.72 | 162.83 | 20.73 | 4.41 |
| FYE June 2025 Revised Plan | 148.61 | 161.88 | 20.49 | 4.38 |

Revenue by Segment Year-on-year

| | FYE June 2024 Results | | FYE June 2025 Results | | | |
|--------------|-----------------------|--------------|-----------------------|--------------|-------------------|--------------|
| | Amount (Mil.Yen) | Ratio (%) | Amount (Mil.Yen) | Ratio (%) | Changes (Mil.Yen) | Changes (%) |
| Medical | 95,654 | 88.9 | 107,779 | 89.8 | +12,124 | +12.7 |
| Device | 11,892 | 11.1 | 12,245 | 10.2 | +353 | +3.0 |
| Total amount | 107,547 | 100.0 | 120,025 | 100.0 | +12,477 | +11.6 |

(Reference)




| | | | | | | |
|---------------|----------------|-------------|----------------|-------------|----------------|--------------|
| Medical Field | 103,180 | 95.9 | 115,799 | 96.5 | +12,618 | +12.2 |
| Device Field | 4,367 | 4.1 | 4,226 | 3.5 | -140 | -3.2 |

Operating Income by Segment Year-on-year

| | FYE June 2024 Results | | FYE June 2025 Results | | | |
|--|-----------------------|-------------------------|-----------------------|-------------------------|----------------------|----------------|
| | Amount (Mil.Yen) | Operating margin (%) | Amount (Mil.Yen) | Operating margin (%) | Changes (Mil.Yen) | Changes (%) |
| Operating income excluding goodwill amortization, etc. | | | | | | |
| Medical | 26,458 | 27.7 | 35,055 | 32.5 | +8,596 | +32.5 |
| Device | 5,287 | 44.5 | 4,624 | 37.8 | -662 | -12.5 |
| Erasing & Head Quarters | -7,577 | – | -7,990 | – | -412 | +5.4 |
| Total | 24,168 | 22.5 | 31,689 | 26.4 | +7,521 | +31.1 |
| Operating income | | | | | | |
| Medical | 24,426 | 25.5 | 33,445 | 31.0 | +9,019 | +36.9 |
| Device | 5,287 | 44.5 | 4,624 | 37.8 | -662 | -12.5 |
| Erasing & Head Quarters | -7,577 | – | -7,990 | – | -412 | +5.4 |
| Total | 22,135 | 20.6 | 30,079 | 25.1 | +7,943 | +35.9 |
| (Reference) | | | | | | |
| Device Division Segment Revenue | 14,257 | – | 14,151 | – | -106 | -0.7 |

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)


Earnings Performance by Segment



※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Headquarters +2,316)


Attribution Analysis of Operating Income - 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income – 2

(Exchange Rate Fluctuations Excluded)



Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)



【Revenue (YoY)】 ~ Increased due to expanding market share, etc.~

- Japan : Increased primarily in Non-cardiovascular field. Extremely limited impact due to reimbursement price.
 - Cardiovascular field : Increased mainly in Penetration Catheter/Purchased products/Guiding Catheter
 - Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra) and increased in Neurovascular products due to the effect of new product
- Overseas : Increased in all regions due to strong demand and expanding market share across all areas
 - US: Brand products progressed favorably despite the decrease in OEM transactions (Brand products, YoY up +13.6%)
 - Cardiovascular field : Increased mainly in PCI GW/Penetration Catheter
 - Non-cardiovascular field : Increased in all fields including Abdominal vascular, Peripheral vascular and Neurovascular products.
 - Europe: Progressed well, overall both direct sales and distribution sales
 - Cardiovascular field : Increased PCI GW and Penetration catheter
 - Non-cardiovascular : Increased Neurovascular and Peripheral vascular products.
 - China: Progressed favorably due to the market growth and expanding market share
 - Cardiovascular field : Increased in PCI GW, Penetration Catheter
 - Non-cardiovascular field : Increased in Neurovascular products
 - OEM Business : Decreased transactions due to business partner trends
 - Other: Progressed well, overall
 - Cardiovascular field : Increased in PCI GW mainly in Asia
 - Non-cardiovascular field : Increased in Neurovascular/ Peripheral vascular mainly in Asia
 - OEM Business : Increased transactions due to business partner trends


【Operating Income】 Operating income increased in proportion to revenue

Per Segment by Medical Division (by Geography-2)

| (Mil. Yen) | | FYE June 2024 Results | FYE June 2025 Results | YoY | |
|------------------------|------|-----------------------|-----------------------|----------------|--------------|
| | | | | Changes | Changes (%) |
| Exchange rate (Yen) | USD | 149.39 | 149.72 | +0.33 | +0.2 |
| | EURO | 161.48 | 162.83 | +1.35 | +0.8 |
| | CNY | 20.64 | 20.73 | +0.09 | +0.4 |
| Total Revenue | | 95,654 | 107,779 | +12,124 | +12.7 |
| Japan | | 14,727 | 16,074 | +1,346 | +9.1 |
| Overseas | | 80,927 | 91,705 | +10,778 | +13.3 |
| US | | 21,066 | 23,043 | +1,977 | +9.4 |
| Europe | | 22,121 | 24,148 | +2,026 | +9.2 |
| China | | 24,033 | 28,283 | +4,250 | +17.7 |
| Other | | 13,705 | 16,229 | +2,523 | +18.4 |
| Operating income | | 24,426 | 33,445 | +9,018 | +36.9 |

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)

Per Segment by Medical Division (by Treatment-1)



Revenue (YoY)

Cardiovascular

- Japan : Increased mainly in Penetration Catheter/Purchased products/Guiding Catheter
- Overseas : Increased in all regions due to expanding market share which is owing to the increase in China
 - Increased primarily in PCI GW and Penetration catheter, etc.

Non-Cardiovascular

- Japan : Strong sales of purchased products in Peripheral vascular (Penumbra) and increased Neurovascular due to the effect of new product
- Overseas : Increased in all regions
 - US : Increased in all fields such as Abdominal, Peripheral and Neurovascular products.
 - Europe : Increased in Neurovascular and Peripheral vascular products
 - China : Increased in Neurovascular products
 - Other : Increased in Neurovascular/Peripheral vascular products mainly in Asia


OEM

- Japan : Decreased transactions due to business partner trends
- Overseas : Decreased transactions for the U.S. and China owing to business partner trends despite the increase of transactions for Asia

Per Segment by Medical Division (by Treatment-2)

| (Mil. Yen) | | FYE June 2024 Results | FYE June 2025 Results | YoY | |
|---|------|---------------------------|---------------------------|----------------------------|-------------------------|
| | | | | Changes | Changes(%) |
| Exchange rate (Yen) | USD | 149.39 | 149.72 | +0.33 | +0.2 |
| | EURO | 161.48 | 162.83 | +1.35 | +0.8 |
| | CNY | 20.64 | 20.73 | +0.09 | +0.4 |
| Total Revenue | | 95,654 | 107,779 | +12,124 | +12.7 |
| Japan Overseas | | 14,727 80,927 | 16,074 91,705 | +1,346 +10,778 | +9.1 +13.3 |
| Cardiovascular Japan Overseas | | 72,690 8,443 64,246 | 81,202 8,629 72,572 | +8,512 +186 +8,326 | +11.7 +2.2 +13.0 |
| Non-Cardiovascular Japan Overseas | | 15,346 4,587 10,758 | 18,983 5,799 13,184 | +3,636 +1,211 +2,425 | +23.7 +26.4 +22.5 |
| OEM Japan Overseas | | 7,618 1,696 5,921 | 7,593 1,645 5,948 | -24 -51 +26 | -0.3 -3.0 +0.5 |

Per Segment by Device Division-1



【Revenue (YoY)】

Slightly increased in medical components and slightly decreased in industrial components

Medical Component

- Japan : Remained flat
- Overseas : Increased transactions of cardiovascular inspection catheter components for Asia

Industrial Component

- Japan : Remained flat
- Overseas : Decreased leisure-related transactions

【Operating income】

Decreased due to a decrease in intersegment transaction, despite the increase in revenue

Per Segment by Device Division-2

| (Mil. Yen) | | FYE June 2024 Results | FYE June 2025 Results | YoY | |
|-----------------------------|----------|-----------------------|-----------------------|--------------|--------------|
| | | | | Changes | Changes (%) |
| Exchange rate (Yen) | USD | 149.39 | 149.72 | +0.33 | +0.2 |
| Total Revenue | | 11,892 | 12,245 | +353 | +3.0 |
| | Japan | 2,732 | 2,805 | +72 | +2.7 |
| | Overseas | 9,159 | 9,439 | +280 | +3.1 |
| Medical Components | | 7,525 | 8,019 | +494 | +6.6 |
| | Japan | 1,082 | 1,103 | +21 | +2.0 |
| | Overseas | 6,443 | 6,916 | +472 | +7.3 |
| Industrial Components | | 4,367 | 4,226 | -140 | -3.2 |
| | Japan | 1,650 | 1,702 | +51 | +3.1 |
| | Overseas | 2,716 | 2,523 | -192 | -7.1 |
| Operating income | | 5,287 | 4,624 | -662 | -12.5 |
| (Reference) Segment Revenue | | 14,257 | 14,151 | -106 | -0.7 |

※ Due to organizational expansion at some overseas subsidiaries, etc., the attribution of administrative costs has been changed from Medical/Device segments to Headquarters segment from FYE June 2025. Therefore, the figures adjusted to reflect the allocation of administrative costs for the period FYE June 2024 in line with FYE June 2025. (Correction effect in FYE June 2024 Medical Division -1,762, Device Division -554 ⇒Erasing/Head quarters +2,316)


Reference: P/L

| | FYE June 2024 Results | | FYE June 2025 Results | | | |
|--|-----------------------|--------------|-----------------------|--------------|--------------------|---|
| | Amount (Mil. Yen) | Ratio (%) | Amount (Mil. Yen) | Ratio (%) | Changes (Mil. Yen) | Main comparison factors |
| Revenue | 107,547 | 100.0 | 120,025 | 100.0 | +12,477 | •Progressed favorably centered in Medical Division |
| Cost of sales | 38,494 | 35.8 | 38,789 | 32.3 | +295 | |
| Gross profit | 69,053 | 64.2 | 81,235 | 67.7 | +12,182 | •Increased in proportion to increasing revenue and gross profit margin |
| SGA | 46,917 | 43.6 | 51,155 | 42.6 | +4,238 | •Increased in expenses related to sales and R&D |
| Operating income excl. goodwill amortization | 24,168 | 22.5 | 31,689 | 26.4 | +7,521 | |
| Operating income | 22,135 | 20.6 | 30,079 | 25.1 | +7,943 | |
| Non-operating income | 515 | 0.5 | 1,401 | 1.2 | +885 | •Increased in subsidy income |
| Non-operating expense | 683 | 0.6 | 1,918 | 1.6 | +1,234 | •Increased in foreign exchange losses |
| Ordinary income | 21,968 | 20.4 | 29,563 | 24.6 | 7,595 | |
| Extraordinary income | 21 | 0.0 | 123 | 0.1 | +102 | |
| Extraordinary loss | 199 | 0.2 | 11,031 | 9.2 | +10,831 | •Recording of impairment losses and increased in loss on valuation of investment securities, etc. |
| Net income attributable to parent company shareholders | 15,808 | 14.7 | 12,737 | 10.6 | -3,070 | |
| Comprehensive income | 22,873 | 21.3 | 9,375 | 7.8 | -13,498 | Decreased in line with the foreign exchange rate fluctuation |

Reference: B/S

| | | FYE June 2024 Results | | FYE June 2025 Results | | | | Main comparison factors | |
|--------------------------------|---------------------|-----------------------|-----------|-----------------------|-----------|--------------------|--|------------------------------|--|
| | | Amount (Mil. Yen) | Ratio (%) | Amount (Mil. Yen) | Ratio (%) | Changes (Mil. Yen) | | | |
| Assets | Current assets | 94,696 | 49.4 | 103,359 | 53.5 | +8,662 | Cash and deposits Inventories | +18,542 -4,692 | |
| | Fixed assets | 96,917 | 50.6 | 89,827 | 46.5 | -7,089 | Goodwill | -6,800 | |
| Total assets | | 191,614 | 100.0 | 193,187 | 100.0 | +1,573 | | | |
| Liabilities | Current liabilities | 29,494 | 15.4 | 27,856 | 14.4 | -1,638 | Short-term borrowings Income taxes payables | -3,228 +2,106 | |
| | Fixed liabilities | 10,157 | 5.3 | 13,976 | 7.2 | +3,818 | Long-term borrowings Deferred tax liabilities | + 5,546 - 2,714 | |
| Total liabilities | | 39,652 | 20.7 | 41,833 | 21.7 | +2,180 | | | |
| Total net assets | | 151,961 | 79.3 | 151,354 | 78.3 | -607 | Retained earnings Treasury stock Foreign currency translation adjustment | +7,204 - 4,446 - 2,826 | |
| Total liabilities & net assets | | 191,614 | 100.0 | 193,187 | 100.0 | +1,573 | | | |

Reference: C/F



Contents

1. Summary of Consolidated Financial Results of FYE
June 2025

2. Earnings Forecast for FYE June 2026

Vision for FYE June 2026

Steady growth in both Medical and Device divisions is expected to boost sales and profits despite negative factors such as the negative impact of assumed exchange rates and increased U.S. tariffs

- Revenue is expected to reach to **130,870 Mil. Yen (YoY +9.0%)** due to growing overseas sales in Medical Division
 - **Revenue YoY at the same exchange rate as the previous year +11.3%**
(Revenue may decrease due to assumed exchange rate trends (yen appreciation) -2,761 million yen)
 - Medical Division: Cardiovascular/Increase in all overseas market
Non-cardiovascular/ Increase in all overseas market and in all fields due to market penetration
 - Device Division: Increase due to the consolidation of Nitta Mold as a subsidiary, with growth in both Medical components and Industrial components
- Operating income is expected to reach to **32,642 Mil. Yen (YoY +8.5%)** despite the impact of exchange rate fluctuation and tariffs
 - **Revenue YoY at the same exchange rate as the previous year +16.9%**
 - **Gross profit 86,786 Mil. Yen (YoY +6.8%)**
 - Despite the productivity improvement, etc., GPM may decrease from 67.7% to 66.3% due to exchange rate trends and the impact of US tariffs, etc. (GPM excluding forex rate 67.2%)
 - **SGA expenses 54,144 Mil. Yen (YoY+5.8%)**
 - Increase in expenses for strengthening sales promotion mainly in the U.S.
 - Increase in R&D expenses (12,900 Mil. Yen, revenue ratio 9.9%)
 - Increase in personnel expenses, etc. to strengthen the management foundation
 - Decrease in goodwill amortization (YoY -1,179 Mil. Yen)
 - **Ordinary income 32,809 Mil. Yen(YoY +11.0%)**
 - **Net income attributable to parent company shareholders:23,811 Mil. Yen (YoY +86.9%)**
 - Decrease in impairment losses (YoY -9,244 Mil. Yen),etc.

| Exchange rate (Unit : JPY) | US\$ | EURO | CNY | BAHT |
|-------------------------------|--------|--------|-------|------|
| FYE June 2026 Plan | 143.00 | 165.00 | 20.00 | 4.60 |
| FYE June 2025 Results | 149.72 | 162.83 | 20.73 | 4.41 |



| Effect of exchange rate on operating income (Main currency) | | | |
|---|--------------------------------|-------|-------------------|
| US \$ | (+ 1 yen influence) : approx. | 148 | Mil. Yen Increase |
| EURO | (+ 1 yen influence) : approx. | 123 | Mil. Yen Increase |
| CNY | (+ 1 yen influence) : approx. | 1,490 | Mil. Yen Increase |
| BAHT | (+0.1 yen influence) : approx. | 372 | Mil. Yen Decrease |

Earnings Forecast for FYE June 2026

| | FYE June 2025 Results | | FYE June 2026 Plan | | | | (Reference) At the same exchange rate as the previous year | | | |
|--|-----------------------|-----------|--------------------|-----------|-------------------|-------------|--|-----------|-------------------|-------------|
| | Amount (Mil.Yen) | Ratio (%) | Amount (Mil.Yen) | Ratio (%) | YoY | | Amount (Mil.Yen) | Ratio (%) | YoY | |
| | | | | | Changes (Mil.Yen) | Changes (%) | | | Changes (Mil.Yen) | Changes (%) |
| Revenue | 120,025 | 100.0 | 130,870 | 100.0 | +10,844 | +9.0 | 133,631 | 100.0 | +13,606 | +11.3 |
| Gross profit | 81,235 | 67.7 | 86,786 | 66.3 | +5,550 | +6.8 | 89,785 | 67.2 | +8,549 | +10.5 |
| Operating income | 30,079 | 25.1 | 32,642 | 24.9 | +2,562 | +8.5 | 35,173 | 26.3 | +5,093 | +16.9 |
| Ordinary income | 29,563 | 24.6 | 32,809 | 25.1 | +3,246 | +11.0 | | | | |
| Net income attributable to parent company shareholders | 12,737 | 10.6 | 23,811 | 18.2 | +11,073 | +86.9 | | | | |
| EPS (Yen) | 46.92 | – | 88.30 | – | +41.38 | +88.2 | | | | |


| Exchange rate (Unit : JPY) | US\$ | EURO | CNY | BAHT |
|----------------------------|--------|--------|-------|------|
| FYE June 2026 Plan | 143.00 | 165.00 | 20.00 | 4.60 |
| FYE June 2025 Results | 149.72 | 162.83 | 20.73 | 4.41 |

Earnings Forecast by Segment




Attribution Analysis of Operating Income - 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income - 2

(Exchange Rate Fluctuations Excluded)



R&D Expenses


Continuing aggressive investment in both new and existing projects
<Criteria : R&D to Revenue ratio upper limit 12%>



Results and Plan for Equipment Installation

**Capital investment is generally complete
although an increase is expected due to the launch of factory in China**

| Main investment matter (Mil. Yen) | FYE June 2022 Results | FYE June 2023 Results | FYE June 2024 Results | FYE June 2025 Results | FYE June 2026 (Plan) |
|-----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------|
| Expansion of New Building in Seto | | 3,559 | 4,224 | | |
| Expansion of Shizuoka R&D Center | | | 776 | 1,099 | |
| Expansion of Thailand factory | 869 | 1,213 | 717 | | 507 |
| Expansion of Hanoi factory | | 1,396 | 1,114 | 1,448 | |
| Expansion of Cebu factory | 1,579 | 749 | | 691 | |
| Launch of factory in China | | | | | 1,536 |



※Excluding amortization transferred to amortization of goodwill, etc.

Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements. Please note that actual results may differ greatly from plans presented here.

[IR contact]

**Asahi Intecc Co., Ltd.
corporate strategic office**

TEL 0561-48-5551
URL <https://www.asahi-intecc.co.jp/en>